PE20060676A1 - Polimorfo cristalino de acetato de bazedoxifeno - Google Patents

Polimorfo cristalino de acetato de bazedoxifeno

Info

Publication number
PE20060676A1
PE20060676A1 PE2005000386A PE2005000386A PE20060676A1 PE 20060676 A1 PE20060676 A1 PE 20060676A1 PE 2005000386 A PE2005000386 A PE 2005000386A PE 2005000386 A PE2005000386 A PE 2005000386A PE 20060676 A1 PE20060676 A1 PE 20060676A1
Authority
PE
Peru
Prior art keywords
acetate
polymorph
crystalline polymorph
bazedoxifen
bazedoxifen acetate
Prior art date
Application number
PE2005000386A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Demerson
Silvio Iera
Kadum Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060676(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060676A1 publication Critical patent/PE20060676A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PE2005000386A 2004-04-07 2005-04-06 Polimorfo cristalino de acetato de bazedoxifeno PE20060676A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56058204P 2004-04-07 2004-04-07
US66017805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
PE20060676A1 true PE20060676A1 (es) 2006-07-24

Family

ID=34966308

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000386A PE20060676A1 (es) 2004-04-07 2005-04-06 Polimorfo cristalino de acetato de bazedoxifeno

Country Status (18)

Country Link
US (1) US7683051B2 (https=)
EP (1) EP1732890A1 (https=)
JP (2) JP2007532560A (https=)
KR (1) KR20060135866A (https=)
AR (1) AR048527A1 (https=)
AU (1) AU2005233133A1 (https=)
BR (1) BRPI0509191A (https=)
CA (1) CA2561010A1 (https=)
CR (1) CR8615A (https=)
EC (1) ECSP066911A (https=)
IL (1) IL178236A0 (https=)
NO (1) NO20065052L (https=)
PA (1) PA8629101A1 (https=)
PE (1) PE20060676A1 (https=)
RU (1) RU2006132180A (https=)
SG (1) SG151331A1 (https=)
TW (1) TWI346105B (https=)
WO (1) WO2005100316A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060676A1 (es) 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
GT200500080A (es) 2004-04-07 2005-10-31 Polimorfo cristalino de acetato de bazedoxifeno
US8538393B1 (en) 2004-09-21 2013-09-17 Advanced Ground Information Systems, Inc. Method to provide ad hoc and password protected digital and voice networks
US10645562B2 (en) 2004-09-21 2020-05-05 Agis Software Development Llc Method to provide ad hoc and password protected digital and voice networks
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
CN101977897A (zh) * 2008-02-11 2011-02-16 惠氏有限责任公司 制备乙酸巴多昔芬的多晶型a的方法
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
WO2009102778A1 (en) * 2008-02-11 2009-08-20 Wyeth Amorphous polymorph of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
AR078785A1 (es) 2009-10-27 2011-11-30 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes
US8154175B2 (en) * 2009-12-16 2012-04-10 Hamilton Sundstrand Corporation Sensing device
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2616463A4 (en) * 2010-09-14 2014-01-08 Reddys Lab Ltd Dr PREPARATION OF CRYSTALLINE BAZEDOXIFES AND THEIR SALTS
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
US9751835B2 (en) 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN111060619B (zh) * 2019-12-18 2022-11-18 北京鑫开元医药科技有限公司 一种醋酸巴多昔芬杂质的检测方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
DE69707189T2 (de) 1996-04-19 2002-06-20 American Home Products Corp., Madison Östrogene Verbindungen
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
NZ503793A (en) 1997-10-15 2002-10-25 Wyeth Corp Novel aryloxy-alkyl-dialkylamines and processes for preparing these compounds
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
IL165395A0 (en) * 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
PE20060676A1 (es) 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno

Also Published As

Publication number Publication date
JP2007532560A (ja) 2007-11-15
BRPI0509191A (pt) 2007-09-25
PA8629101A1 (es) 2005-11-25
KR20060135866A (ko) 2006-12-29
TWI346105B (en) 2011-08-01
SG151331A1 (en) 2009-04-30
EP1732890A1 (en) 2006-12-20
AR048527A1 (es) 2006-05-03
TW200606149A (en) 2006-02-16
CA2561010A1 (en) 2005-10-27
WO2005100316A1 (en) 2005-10-27
US7683051B2 (en) 2010-03-23
NO20065052L (no) 2006-11-06
RU2006132180A (ru) 2008-05-20
JP2009035535A (ja) 2009-02-19
US20050227965A1 (en) 2005-10-13
AU2005233133A1 (en) 2005-10-27
CR8615A (es) 2007-06-06
ECSP066911A (es) 2006-12-20
IL178236A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
PE20060676A1 (es) Polimorfo cristalino de acetato de bazedoxifeno
AR129907A2 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO, COMPOSICIÓN FARMACÉUTICA, PROCESO PARA LA PREPARACIÓN Y USOS
BRPI0817154A2 (pt) "método de modificar uma célula de levedura para a produção de etanol, célula de levedura modificada, uso de uma célula de levedura modificada e método para a produção de etanol"
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
AR077203A1 (es) Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms)
BR112015006075A2 (pt) composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
MX363983B (es) Compuestos de enaminocarbonilo sustituidos.
BRPI0811809A2 (pt) "método para produzir um produto baseado em fermentação e método para produzir etanol"
NZ600207A (en) Substituted 4-aminocyclohexane derivatives
NZ716349A (en) Compositions and methods for stimulating hair growth
ATE514692T1 (de) Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IL193951A (en) A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound.
WO2010036998A3 (en) Indole and indoline derivatives and methods of use thereof
WO2009002427A3 (en) Methods of synthesizing cinacalcet and salts thereof
WO2011008312A3 (en) Indole and indoline derivatives and methods of use thereof
CR20120058A (es) Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina
NZ591814A (en) Pesticidal composition comprising an alpha-alkoxyphenyl acetic acid derivative and a neonicotinoid compound
IL216228A0 (en) 5-membered heterocyclic compound cyclopenta[c] pyrrolylakyl carbamate derivaties, preparation thereof, and therapeutic use thereof
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
JP2010507589A5 (ja) Ｃｂ１受容体モジュレーターとしての１，５−ジフェニル−３−ピリジニルアミノ−１，５−ジヒドロピロリジン−２−オン
WO2008048648A3 (en) Cb1-modulating compounds and their use
AR073527A1 (es) Forma cristalina de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico
WO2010002835A3 (en) Vinpocetine and eburnamonine derivatives for promoting bone growth
ATE520393T1 (de) Verwendung von cb1-rezeptor-antagonisten zur herstellung eines arzneimittels zur behandlung von lebererkrankungen
WO2009037586A3 (en) Use of peptidic vasopressin receptor agonists

Legal Events

Date Code Title Description
FC Refusal